Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Solid Tumors
Filter by Topic
Bladder Cancer
Breast Cancer
Colon Cancer
Colorectal Cancer
Gastric Cancer
Genitourinary Cancers
GI Cancers
Gynecologic Cancer
Head and Neck Cancer
Liver Cancer
Lung Cancer
Melanoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Thyroid Cancer
No Clear Selection Criteria for Genomic Testing in Patients with Metastatic Colorectal Cancer
By
Charles Bankhead
Colorectal Cancer
,
Solid Tumors
October 2016, Vol 7, No 9
Read Article
Role of Cancer Cell Count in Assessing Therapy Efficacy in Prostate Cancer
By
Sophie Granger
Prostate Cancer
,
Solid Tumors
October 2016, Vol 7, No 9
Read Article
HF10 plus Ipilimumab Increases Response Rates in Metastatic Melanoma
By
Walter Alexander
Melanoma
,
Solid Tumors
September 2016, Vol 7, No 8
When combined with systemic ipilimumab (Yervoy), the investigational oncolytic viral immunotherapy HF10, a mutation of the HF strain of the herpes simplex virus type 1 (HSV-1), has local and systemic activity in patients with metastatic melanoma, said Robert Andtbacka, MD, CM, Huntsman Cancer Institute, Salt Lake City, during a poster presentation at the 2016 American Society of Clinical Oncology meeting. He added that HF10 substantially improves the response rate of ipilimumab alone and does not exacerbate ipilimumab toxicity.
Read Article
Adding Capecitabine to Gemcitabine Chemotherapy After Pancreatic Cancer Surgery Improves Survival
By
Walter Alexander
Pancreatic Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Adding capecitabine chemotherapy to gemcitabine after pancreatic cancer resection was associated with longer overall survival (OS) than gemcitabine chemotherapy alone, according to results from the European Study Group for Pancreatic Cancer (ESPAC)-4 clinical trial. For the small proportion of patients with pancreatic cancer who are candidates for surgery, adjuvant gemcitabine chemotherapy is the current standard of care worldwide, said John P. Neoptolemos, MD, Chair of Surgery, University of Liverpool, United Kingdom, during an oral abstract session at the 2016 American Society of Clinical Oncology annual meeting. “We thought that the combination of gemcitabine plus capecitabine…may be better than gemcitabine alone, and launched the phase 3 ESPAC-4 trial,” he stated.
Read Article
ESMO Consensus Guidelines for Metastatic Colorectal Cancer Offer Widely Expanded Recommendations
By
Walter Alexander
Colorectal Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Read Article
Nearly Half of Pancreatic Cancer Surgery Candidates Are Not Offered that Option
By
Charles Bankhead
Pancreatic Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Pancreatic cancer is the third leading cause of cancer-related death in the United States. Nearly half of patients with locoregional pancreatic cancer do not undergo potentially curative surgery, primarily because of nonclinical factors, according to the results of an analysis of data from the National Cancer Institute database by Amy T. Cunningham, MPH, a doctoral candidate at Thomas Jefferson University in Philadelphia, and colleagues.
Read Article
Baseline BMD Testing Suboptimal in Older Women with Breast Cancer Starting Aromatase Inhibitor Therapy
By
Alice Goodman
Breast Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Approximately 33% of older women with early-stage breast cancer are not being tested for bone mineral density (BMD) before starting aromatase inhibitor therapy, according to a new and to date the largest population-based study on this topic (Charlson J, et al.
J Natl Compr Canc Netw
. 2016;14:875-880).
Read Article
Changes in Patient-Reported Outcomes Linked to Better Survival in Metastatic Prostate Cancer
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
Patient-reported outcomes had significant associations with survival in metastatic castration-resistant prostate cancer (mCRPC), suggesting potential implications for clinical management, reported Tomasz M. Beer, MD, Oregon Health & Science University, Knight Cancer Institute, Portland, and colleagues, at the 2016 International Society for Pharmacoeconomics and Outcomes Research annual meeting.
Read Article
Rise in Metastatic Prostate Cancer Has Screening, Treatment Implications
By
Charles Bankhead
Prostate Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
The incidence of metastatic prostate cancer increased by >70% from 2004 to 2013, including >90% in the age-group most likely to benefit from definitive treatment, according to a new analysis of a national database (Weiner AB, et al.
Prostate Cancer Prostatic Dis
. 2016 Jul 19. Epub ahead of print).
Read Article
Concurrent Radiation and Temozolomide Lowers Risk for Death in Elderly Patients with Glioblastoma
By
Walter Alexander
Brain Cancer
,
Solid Tumors
September 2016, Vol 7, No 8
The first study to assess the addition of temozolomide (Temodar) chemotherapy during short-course radiation therapy, followed by monthly maintenance of temozolomide in elderly patients with glioblastoma showed a significantly reduced risk for death, said the study co-author James R. Perry, MD, FRCPC, The Crolla Family Endowed Chair in Brain Tumour Research, Odette Cancer and Sunnybrook Health Sciences Centres, Toronto, Canada, in a plenary session at the 2016 American Society of Clinical Oncology annual meeting.
Read Article
Page 5 of 16
1
2
3
4
5
6
7
8
9
10
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma